GW679769
NKT102245
Phase 2 small_molecule completed
Quick answer
GW679769 for Postoperative Nausea and Vomiting is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Postoperative Nausea and Vomiting
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed